https://www.thehindubusinessline.com/news/national/a-continuous-glucose-monitoring-device-problem-flags-need-for-better-customer-redressal-mechanisms/article70901101 ...

This resource was independently developed by AJMC and funded by an Independent Medical Education Grant from DexCom, Inc. This actionable resource explores the rising need for continuous glucose ...

A major clinical trial has found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults living with type 2 diabetes who are treated with basal ...

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...

When diabetes patients track their blood sugar with a 24-hour wearable device, they manage their glucose more precisely and reduce the risk of hypoglycemia and other problems. In 1999, the U.S. Food ...

Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Brendan is a full-time senior editor of financial products and services at ...

Historically, pharmaceutical products have been produced in a traditional ‘batch’ system, in which every operation is executed separately using a defined quantity of materials. In batch manufacturing ...

(Bloomberg) -- Danaher Corp. is nearing a roughly $10 billion deal to acquire US medical technology firm Masimo Corp., the Financial Times reported, citing unidentified people familiar with the matter ...